Skip to main content
Erschienen in: Current Heart Failure Reports 3/2012

01.09.2012 | Decompensated Heart Failure (MM Givertz, Section editor)

Congestion Is the Driving Force Behind Heart Failure

verfasst von: Maya Guglin

Erschienen in: Current Heart Failure Reports | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Increased filling pressures, or congestion, cause symptoms of heart failure and lead to hospitalizations. A higher rate of hospitalizations determines higher mortality. The most reliable way to decrease admissions is to monitor for signs of congestion, by history and exam, intracardiac pressures or biomarkers, and to modify treatment based on these data. The role of congestion is best understood by comparison of heart failure with preserved and reduced ejection fraction. The morbidity and mortality in both conditions is almost identical. Decreased cardiac output and ventricular remodeling play a major role in patients with decreased ejection fraction but not in those with preserved ejection fraction. The key factor that is present in both conditions and determines their similarity is congestion. Decongestion, or fluid removal, is the most effective treatment for heart failure regardless of ejection fraction. Being the driving force of heart failure, congestion should be the focus of clinical and hemodynamic monitoring and therapy.
Literatur
1.
Zurück zum Zitat Yancy CW, Fonarow GC, Committee ASA. Quality of care and outcomes in acute decompensated heart failure: the ADHERE registry. Curr Heart Fail Rep. 2004;1:121–8.PubMedCrossRef Yancy CW, Fonarow GC, Committee ASA. Quality of care and outcomes in acute decompensated heart failure: the ADHERE registry. Curr Heart Fail Rep. 2004;1:121–8.PubMedCrossRef
2.
Zurück zum Zitat Tallaj JAP, Aaron M, Abraham W, Heywood JBR, Cho Y, Bennett T. Relationship between right ventricular pressures and heart failure events in patients with heart failure. J Card Fail. 2007;13:S178–9.CrossRef Tallaj JAP, Aaron M, Abraham W, Heywood JBR, Cho Y, Bennett T. Relationship between right ventricular pressures and heart failure events in patients with heart failure. J Card Fail. 2007;13:S178–9.CrossRef
3.
Zurück zum Zitat Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118:1433–41.PubMedCrossRef Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118:1433–41.PubMedCrossRef
4.
Zurück zum Zitat •• Stevenson LW, Zile M, Bennett TD, Kueffer FJ, Jessup ML, Adamson P, et al. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail. 2010;3:580–7. This paper demonstrates the importance of congestion and its management for hospital admissions.PubMedCrossRef •• Stevenson LW, Zile M, Bennett TD, Kueffer FJ, Jessup ML, Adamson P, et al. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail. 2010;3:580–7. This paper demonstrates the importance of congestion and its management for hospital admissions.PubMedCrossRef
5.
Zurück zum Zitat Adamson PB, Magalski A, Braunschweig F, Bohm M, Reynolds D, Steinhaus D, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003;41:565–71.PubMedCrossRef Adamson PB, Magalski A, Braunschweig F, Bohm M, Reynolds D, Steinhaus D, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003;41:565–71.PubMedCrossRef
6.
Zurück zum Zitat •• Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–66. This article on the results of the CHAMPION trial demonstrates reduction in heart failure admission rates with hemodynamic monitoring.PubMedCrossRef •• Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–66. This article on the results of the CHAMPION trial demonstrates reduction in heart failure admission rates with hemodynamic monitoring.PubMedCrossRef
7.
Zurück zum Zitat • Sharma GV, Woods PA, Lindsey N, O’Connell C, Connolly L, Joseph J, et al. Noninvasive monitoring of left ventricular end-diastolic pressure reduces rehospitalization rates in patients hospitalized for heart failure: a randomized controlled trial. J Card Fail. 2011;17:718–25. This paper further develops the idea of benefits of guiding the therapy in heart failure by hemodynamic parameters.PubMedCrossRef • Sharma GV, Woods PA, Lindsey N, O’Connell C, Connolly L, Joseph J, et al. Noninvasive monitoring of left ventricular end-diastolic pressure reduces rehospitalization rates in patients hospitalized for heart failure: a randomized controlled trial. J Card Fail. 2011;17:718–25. This paper further develops the idea of benefits of guiding the therapy in heart failure by hemodynamic parameters.PubMedCrossRef
8.
Zurück zum Zitat Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol. 2007;49:1733–9.PubMedCrossRef Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol. 2007;49:1733–9.PubMedCrossRef
9.
Zurück zum Zitat •• Januzzi Jr JL, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58:1881–9. This article is interesting in several respects: it shows the importance of BNP-guided strategy, and highlights the interactions between systolic function and congestion.PubMedCrossRef •• Januzzi Jr JL, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58:1881–9. This article is interesting in several respects: it shows the importance of BNP-guided strategy, and highlights the interactions between systolic function and congestion.PubMedCrossRef
10.
Zurück zum Zitat Lee DAP, Stukel T, Alter D, Chong A, PArker J, Tu J. “Dose-dependent” impact of recurrent cardiac events on mortality in patients with heart failure. Am J Med. 2009;122:162.e1–.e9.CrossRef Lee DAP, Stukel T, Alter D, Chong A, PArker J, Tu J. “Dose-dependent” impact of recurrent cardiac events on mortality in patients with heart failure. Am J Med. 2009;122:162.e1–.e9.CrossRef
11.
Zurück zum Zitat •• Guglin M. Key role of congestion in natural history of heart failure. Int J Gen Med. 2011;4:585–91. This paper underscores the inconsistencies in current understanding of the concept of heart failure, and suggests a new model explaining all varieties of the disease.PubMed •• Guglin M. Key role of congestion in natural history of heart failure. Int J Gen Med. 2011;4:585–91. This paper underscores the inconsistencies in current understanding of the concept of heart failure, and suggests a new model explaining all varieties of the disease.PubMed
12.
Zurück zum Zitat Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Hear Fail. 2010;12:974–82.CrossRef Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Hear Fail. 2010;12:974–82.CrossRef
13.
Zurück zum Zitat Kjaergaard J, Akkan D, Iversen KK, Kjoller E, Kober L, Torp-Pedersen C, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007;99:1146–50.PubMedCrossRef Kjaergaard J, Akkan D, Iversen KK, Kjoller E, Kober L, Torp-Pedersen C, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007;99:1146–50.PubMedCrossRef
14.
Zurück zum Zitat Kjaergaard J, Akkan D, Iversen KK, Kober L, Torp-Pedersen C, Hassager C. Right ventricular dysfunction as an independent predictor of short- and long-term mortality in patients with heart failure. Eur J Heart Fail. 2007;9:610–6.PubMedCrossRef Kjaergaard J, Akkan D, Iversen KK, Kober L, Torp-Pedersen C, Hassager C. Right ventricular dysfunction as an independent predictor of short- and long-term mortality in patients with heart failure. Eur J Heart Fail. 2007;9:610–6.PubMedCrossRef
15.
Zurück zum Zitat •• Bursi F, McNallan SM, Redfield MM, Nkomo VT, Lam CS, Weston SA, et al. Pulmonary pressures and death in heart failure a community study. J Am Coll Cardiol. 2012;59:222–31. This study from Mayo Clinic shows the importance of pulmonary hypertension as a prognostic factor in heart failure.PubMedCrossRef •• Bursi F, McNallan SM, Redfield MM, Nkomo VT, Lam CS, Weston SA, et al. Pulmonary pressures and death in heart failure a community study. J Am Coll Cardiol. 2012;59:222–31. This study from Mayo Clinic shows the importance of pulmonary hypertension as a prognostic factor in heart failure.PubMedCrossRef
16.
Zurück zum Zitat Neuman Y, Kotliroff A, Bental T, Siegel RJ, David D, Lishner M. Pulmonary artery pressure and diastolic dysfunction in normal left ventricular systolic function. Int J Cardiol. 2007. Neuman Y, Kotliroff A, Bental T, Siegel RJ, David D, Lishner M. Pulmonary artery pressure and diastolic dysfunction in normal left ventricular systolic function. Int J Cardiol. 2007.
17.
Zurück zum Zitat Dini FL, Nuti R, Barsotti L, Baldini U, Dell’Anna R, Micheli G. Doppler-derived mitral and pulmonary venous flow variables are predictors of pulmonary hypertension in dilated cardiomyopathy. Echocardiography. 2002;19:457–65.PubMedCrossRef Dini FL, Nuti R, Barsotti L, Baldini U, Dell’Anna R, Micheli G. Doppler-derived mitral and pulmonary venous flow variables are predictors of pulmonary hypertension in dilated cardiomyopathy. Echocardiography. 2002;19:457–65.PubMedCrossRef
18.
Zurück zum Zitat Enriquez-Sarano M, Rossi A, Seward JB, Bailey KR, Tajik AJ. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol. 1997;29:153–9.PubMedCrossRef Enriquez-Sarano M, Rossi A, Seward JB, Bailey KR, Tajik AJ. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol. 1997;29:153–9.PubMedCrossRef
19.
Zurück zum Zitat Guglin M. Pulmonary vasodilation in acute and chronic heart failure: empiricism and evidence. Curr Heart Fail Rep. 2011;8:219–25.PubMedCrossRef Guglin M. Pulmonary vasodilation in acute and chronic heart failure: empiricism and evidence. Curr Heart Fail Rep. 2011;8:219–25.PubMedCrossRef
20.
Zurück zum Zitat • Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164–74. This study demonstrated hemodynamic and clinical benefits of sildenafil in heart failure with preserved systolic function.PubMedCrossRef • Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124:164–74. This study demonstrated hemodynamic and clinical benefits of sildenafil in heart failure with preserved systolic function.PubMedCrossRef
21.
Zurück zum Zitat Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13:422–30.PubMedCrossRef Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13:422–30.PubMedCrossRef
22.
Zurück zum Zitat Maeder MHD, Kaye D. Does tricuspid regurgitation contribute to renal dysfunction in patients with heart failure. J Card Fail. 2008;14:S84.CrossRef Maeder MHD, Kaye D. Does tricuspid regurgitation contribute to renal dysfunction in patients with heart failure. J Card Fail. 2008;14:S84.CrossRef
23.
Zurück zum Zitat Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–96.PubMedCrossRef Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–96.PubMedCrossRef
24.
Zurück zum Zitat Guglin M, Rivero A, Matar F, Garcia M. Renal dysfunction in heart failure is due to congestion but not low output. Clin Cardiol. 2011;34:113–6.PubMedCrossRef Guglin M, Rivero A, Matar F, Garcia M. Renal dysfunction in heart failure is due to congestion but not low output. Clin Cardiol. 2011;34:113–6.PubMedCrossRef
25.
Zurück zum Zitat Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.PubMedCrossRef Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.PubMedCrossRef
26.
Zurück zum Zitat Ansari M, Alexander M, Tutar A, Massie BM. Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic function. Am Heart J. 2003;146:115–20.PubMedCrossRef Ansari M, Alexander M, Tutar A, Massie BM. Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic function. Am Heart J. 2003;146:115–20.PubMedCrossRef
27.
Zurück zum Zitat Berry C, Hogg K, Norrie J, Stevenson K, Brett M, McMurray J. Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart. 2005;91:907–13.PubMedCrossRef Berry C, Hogg K, Norrie J, Stevenson K, Brett M, McMurray J. Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart. 2005;91:907–13.PubMedCrossRef
28.
Zurück zum Zitat Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. JAMA: J Am Med Assoc. 2006;296:2209–16.CrossRef Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. JAMA: J Am Med Assoc. 2006;296:2209–16.CrossRef
29.
Zurück zum Zitat Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol. 2007;50:768–77.PubMedCrossRef Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol. 2007;50:768–77.PubMedCrossRef
30.
Zurück zum Zitat Varela-Roman A, Gonzalez-Juanatey JR, Basante P, Trillo R, Garcia-Seara J, Martinez-Sande JL, et al. Clinical characteristics and prognosis of hospitalised inpatients with heart failure and preserved or reduced left ventricular ejection fraction. Heart. 2002;88:249–54.PubMedCrossRef Varela-Roman A, Gonzalez-Juanatey JR, Basante P, Trillo R, Garcia-Seara J, Martinez-Sande JL, et al. Clinical characteristics and prognosis of hospitalised inpatients with heart failure and preserved or reduced left ventricular ejection fraction. Heart. 2002;88:249–54.PubMedCrossRef
31.
Zurück zum Zitat Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260–9.PubMedCrossRef Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260–9.PubMedCrossRef
32.
Zurück zum Zitat Varela-Roman A, Grigorian L, Barge E, Bassante P, de la Pena MG, Gonzalez-Juanatey JR. Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. Heart (British Cardiac Society). 2005;91:489–94.CrossRef Varela-Roman A, Grigorian L, Barge E, Bassante P, de la Pena MG, Gonzalez-Juanatey JR. Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. Heart (British Cardiac Society). 2005;91:489–94.CrossRef
33.
Zurück zum Zitat Senni M, Redfield MM. Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol. 2001;38:1277–82.PubMedCrossRef Senni M, Redfield MM. Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol. 2001;38:1277–82.PubMedCrossRef
34.
Zurück zum Zitat Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948–55.PubMedCrossRef Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948–55.PubMedCrossRef
35.
Zurück zum Zitat Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55 %) versus those with mildly reduced (40 % to 55 %) and moderately to severely reduced (<40 %) fractions. Am J Cardiol. 2008;101:1151–6.PubMedCrossRef Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55 %) versus those with mildly reduced (40 % to 55 %) and moderately to severely reduced (<40 %) fractions. Am J Cardiol. 2008;101:1151–6.PubMedCrossRef
36.
Zurück zum Zitat Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2011. doi:10.1093/eurheartj/ehr254 Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2011. doi:10.​1093/​eurheartj/​ehr254
37.
Zurück zum Zitat Grigorian-Shamagian L, Otero Ravina F, Abu Assi E, Vidal Perez R, Teijeira-Fernandez E, Varela Roman A, et al. Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study. Am Hear J. 2008;156:1184–90.CrossRef Grigorian-Shamagian L, Otero Ravina F, Abu Assi E, Vidal Perez R, Teijeira-Fernandez E, Varela Roman A, et al. Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study. Am Hear J. 2008;156:1184–90.CrossRef
38.
Zurück zum Zitat Al-Khatib SM, Shaw LK, O’Connor C, Kong M, Califf RM. Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. J Cardiovasc Electrophysiol. 2007;18:1231–5.PubMedCrossRef Al-Khatib SM, Shaw LK, O’Connor C, Kong M, Califf RM. Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. J Cardiovasc Electrophysiol. 2007;18:1231–5.PubMedCrossRef
39.
Zurück zum Zitat Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362:777–81.PubMedCrossRef Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362:777–81.PubMedCrossRef
40.
Zurück zum Zitat Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–45.PubMedCrossRef Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–45.PubMedCrossRef
41.
Zurück zum Zitat Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–67.PubMedCrossRef Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–67.PubMedCrossRef
43.
Zurück zum Zitat Maurer MS, King DL, El-Khoury Rumbarger L, Packer M, Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail. 2005;11:177–87.PubMedCrossRef Maurer MS, King DL, El-Khoury Rumbarger L, Packer M, Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail. 2005;11:177–87.PubMedCrossRef
44.
Zurück zum Zitat Maurer MS, Burkhoff D, Fried LP, Gottdiener J, King DL, Kitzman DW. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the cardiovascular health study. J Am Coll Cardiol. 2007;49:972–81.PubMedCrossRef Maurer MS, Burkhoff D, Fried LP, Gottdiener J, King DL, Kitzman DW. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the cardiovascular health study. J Am Coll Cardiol. 2007;49:972–81.PubMedCrossRef
45.
Zurück zum Zitat Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982–90.PubMedCrossRef Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982–90.PubMedCrossRef
46.
Zurück zum Zitat Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002;105:1503–8.PubMedCrossRef Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation. 2002;105:1503–8.PubMedCrossRef
47.
Zurück zum Zitat Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation. 2005;112:2254–62.PubMedCrossRef Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation. 2005;112:2254–62.PubMedCrossRef
48.
Zurück zum Zitat Victor BM, Barron JT. Diastolic heart failure versus diastolic dysfunction: difference in renal function. Clin Cardiol. 2010;33:770–4.PubMedCrossRef Victor BM, Barron JT. Diastolic heart failure versus diastolic dysfunction: difference in renal function. Clin Cardiol. 2010;33:770–4.PubMedCrossRef
49.
Zurück zum Zitat Bowling CB, Feller MA, Mujib M, Pawar PP, Zhang Y, Ekundayo OJ, et al. Relationship between stage of kidney disease and incident heart failure in older adults. Am J Nephrol. 2011;34:135–41.PubMedCrossRef Bowling CB, Feller MA, Mujib M, Pawar PP, Zhang Y, Ekundayo OJ, et al. Relationship between stage of kidney disease and incident heart failure in older adults. Am J Nephrol. 2011;34:135–41.PubMedCrossRef
50.
Zurück zum Zitat Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. Circ Heart Fail. 2008;1:91–7.PubMedCrossRef Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. Circ Heart Fail. 2008;1:91–7.PubMedCrossRef
51.
Zurück zum Zitat Zafrir B, Paz H, Wolff R, Salman N, Merhavi D, Lewis BS, et al. Mortality rates and modes of death in heart failure patients with reduced versus preserved systolic function. Eur J Intern Med. 2011;22:53–6.PubMedCrossRef Zafrir B, Paz H, Wolff R, Salman N, Merhavi D, Lewis BS, et al. Mortality rates and modes of death in heart failure patients with reduced versus preserved systolic function. Eur J Intern Med. 2011;22:53–6.PubMedCrossRef
52.
Zurück zum Zitat Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the irbesartan in heart failure with preserved ejection fraction study (I-preserve) trial. Circulation. 2010;121:1393–405.PubMedCrossRef Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the irbesartan in heart failure with preserved ejection fraction study (I-preserve) trial. Circulation. 2010;121:1393–405.PubMedCrossRef
53.
Zurück zum Zitat Grigorian Shamagian L, Gonzalez-Juanatey JR, Roman AV, Acuna JM, Lamela AV. The death rate among hospitalized heart failure patients with normal and depressed left ventricular ejection fraction in the year following discharge: evolution over a 10-year period. Eur Heart J. 2005;26:2251–8.PubMedCrossRef Grigorian Shamagian L, Gonzalez-Juanatey JR, Roman AV, Acuna JM, Lamela AV. The death rate among hospitalized heart failure patients with normal and depressed left ventricular ejection fraction in the year following discharge: evolution over a 10-year period. Eur Heart J. 2005;26:2251–8.PubMedCrossRef
54.
Zurück zum Zitat Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol. 2006;47:76–84.PubMedCrossRef Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol. 2006;47:76–84.PubMedCrossRef
55.
Zurück zum Zitat Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, Sutton GC. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet. 1987;2:709–11.PubMedCrossRef Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, Sutton GC. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet. 1987;2:709–11.PubMedCrossRef
56.
Zurück zum Zitat Cowley AJ, Stainer K, Wynne RD, Rowley JM, Hampton JR. Symptomatic assessment of patients with heart failure: double-blind comparison of increasing doses of diuretics and captopril in moderate heart failure. Lancet. 1986;2:770–2.PubMedCrossRef Cowley AJ, Stainer K, Wynne RD, Rowley JM, Hampton JR. Symptomatic assessment of patients with heart failure: double-blind comparison of increasing doses of diuretics and captopril in moderate heart failure. Lancet. 1986;2:770–2.PubMedCrossRef
57.
Zurück zum Zitat van Kraaij DJ, Jansen RW, Bruijns E, Gribnau FW, Hoefnagels WH. Diuretic usage and withdrawal patterns in a Dutch geriatric patient population. J Am Geriatr Soc. 1997;45:918–22.PubMed van Kraaij DJ, Jansen RW, Bruijns E, Gribnau FW, Hoefnagels WH. Diuretic usage and withdrawal patterns in a Dutch geriatric patient population. J Am Geriatr Soc. 1997;45:918–22.PubMed
58.
Zurück zum Zitat Mathur PN, Pugsley SO, Powles AC, McEwan MP, Campbell EJ. Effect of diuretics on cardiopulmonary performance in severe chronic airflow obstruction. A controlled clinical trial. Arch Intern Med. 1984;144:2154–7.PubMedCrossRef Mathur PN, Pugsley SO, Powles AC, McEwan MP, Campbell EJ. Effect of diuretics on cardiopulmonary performance in severe chronic airflow obstruction. A controlled clinical trial. Arch Intern Med. 1984;144:2154–7.PubMedCrossRef
59.
Zurück zum Zitat Andrews R, Charlesworth A, Evans A, Cowley AJ. A double-blind, cross-over comparison of the effects of a loop diuretic and a dopamine receptor agonist as first line therapy in patients with mild congestive heart failure. Eur Heart J. 1997;18:852–7.PubMedCrossRef Andrews R, Charlesworth A, Evans A, Cowley AJ. A double-blind, cross-over comparison of the effects of a loop diuretic and a dopamine receptor agonist as first line therapy in patients with mild congestive heart failure. Eur Heart J. 1997;18:852–7.PubMedCrossRef
60.
Zurück zum Zitat Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol. 1994;73:881–6.PubMedCrossRef Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol. 1994;73:881–6.PubMedCrossRef
61.
Zurück zum Zitat Ahmed A, Young JB, Love TE, Levesque R, Pitt B. A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol. 2008;125:246–53.PubMedCrossRef Ahmed A, Young JB, Love TE, Levesque R, Pitt B. A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol. 2008;125:246–53.PubMedCrossRef
62.
Zurück zum Zitat Neuberg GW, Miller AB, O’Connor CM, Belkin RN, Carson PE, Cropp AB, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31–8.PubMedCrossRef Neuberg GW, Miller AB, O’Connor CM, Belkin RN, Carson PE, Cropp AB, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31–8.PubMedCrossRef
63.
Zurück zum Zitat Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759–64.PubMedCrossRef Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759–64.PubMedCrossRef
64.
Zurück zum Zitat Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705–8.PubMedCrossRef Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705–8.PubMedCrossRef
65.
Zurück zum Zitat • Guglin M. Reappraisal of the role of diuretics in heart failure. Cardiol Rev. 2009;17:56–9. This is a critical analysis of the existing literature on diuretics in heart failure.PubMedCrossRef • Guglin M. Reappraisal of the role of diuretics in heart failure. Cardiol Rev. 2009;17:56–9. This is a critical analysis of the existing literature on diuretics in heart failure.PubMedCrossRef
66.
Zurück zum Zitat Mielniczuk LM, Tsang SW, Desai AS, Nohria A, Lewis EF, Fang JC, et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail. 2008;14:388–93. This study introduces the concept that high dose of diuretics is a marker but not the cause of instability in heart failure.PubMedCrossRef Mielniczuk LM, Tsang SW, Desai AS, Nohria A, Lewis EF, Fang JC, et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail. 2008;14:388–93. This study introduces the concept that high dose of diuretics is a marker but not the cause of instability in heart failure.PubMedCrossRef
67.
Zurück zum Zitat Guglin M. Diuretics as pathogenetic treatment for heart failure. Int J Gen Med. 2011;4:91–8.PubMed Guglin M. Diuretics as pathogenetic treatment for heart failure. Int J Gen Med. 2011;4:91–8.PubMed
68.
Zurück zum Zitat •• Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122:265–72. This is a subanalysis of the ESCAPE trial showing mortality benefits from aggressive diuresis.PubMedCrossRef •• Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122:265–72. This is a subanalysis of the ESCAPE trial showing mortality benefits from aggressive diuresis.PubMedCrossRef
69.
Zurück zum Zitat Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.PubMedCrossRef Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.PubMedCrossRef
70.
Zurück zum Zitat Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442–51.PubMedCrossRef Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442–51.PubMedCrossRef
71.
Zurück zum Zitat Rubboli A, Sobotka PA, Euler DE. Effect of acute edema on left ventricular function and coronary vascular resistance in the isolated rat heart. Am J Physiol. 1994;267:H1054–61.PubMed Rubboli A, Sobotka PA, Euler DE. Effect of acute edema on left ventricular function and coronary vascular resistance in the isolated rat heart. Am J Physiol. 1994;267:H1054–61.PubMed
72.
Zurück zum Zitat Parrinello G, Paterna S, Di Pasquale P, Torres D, Mezzero M, Cardillo M, et al. Changes in estimating echocardiography pulmonary capillary wedge pressure after hypersaline plus furosemide versus furosemide alone in decompensated heart failure. J Card Fail. 2011;17:331–9.PubMedCrossRef Parrinello G, Paterna S, Di Pasquale P, Torres D, Mezzero M, Cardillo M, et al. Changes in estimating echocardiography pulmonary capillary wedge pressure after hypersaline plus furosemide versus furosemide alone in decompensated heart failure. J Card Fail. 2011;17:331–9.PubMedCrossRef
73.
Zurück zum Zitat Ip JE, Cheung JW, Park D, Hellawell JL, Stein KM, Iwai S, et al. Temporal associations between thoracic volume overload and malignant ventricular arrhythmias: a study of intrathoracic impedance. J Cardiovasc Electrophysiol. 2011;22:293–9.PubMedCrossRef Ip JE, Cheung JW, Park D, Hellawell JL, Stein KM, Iwai S, et al. Temporal associations between thoracic volume overload and malignant ventricular arrhythmias: a study of intrathoracic impedance. J Cardiovasc Electrophysiol. 2011;22:293–9.PubMedCrossRef
74.
Zurück zum Zitat Moore HJ, Peters MN, Franz MR, Karasik PE, Singh SN, Fletcher RD. Intrathoracic impedance preceding ventricular tachyarrhythmia episodes. Pacing Clin Electrophysiol. 2010;33:960–6.PubMed Moore HJ, Peters MN, Franz MR, Karasik PE, Singh SN, Fletcher RD. Intrathoracic impedance preceding ventricular tachyarrhythmia episodes. Pacing Clin Electrophysiol. 2010;33:960–6.PubMed
Metadaten
Titel
Congestion Is the Driving Force Behind Heart Failure
verfasst von
Maya Guglin
Publikationsdatum
01.09.2012
Verlag
Current Science Inc.
Erschienen in
Current Heart Failure Reports / Ausgabe 3/2012
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-012-0093-9

Weitere Artikel der Ausgabe 3/2012

Current Heart Failure Reports 3/2012 Zur Ausgabe

Investigative Therapies (J.-L. Balligand, Section editor)

New Treatment Options for Late Na Current, Arrhythmias, and Diastolic Dysfunction

Investigative Therapies (J.-L. Balligand, Section editor)

AMP-activated Protein Kinase in the Control of Cardiac Metabolism and Remodeling

Decompensated Heart Failure (MM Givertz, Section editor)

Mechanical Circulatory Support in Children: Bridge to Transplant Versus Recovery

Decompensated Heart Failure (MM Givertz, Section editor)

Diuretic Dosing in Acute Decompensated Heart Failure: Lessons from DOSE

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.